Cover Image

Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary

Background - Single-site carcinoma of unknown primary (CUP) is recognised as a distinct favourable subtype in the European Society of Medical Oncology (ESMO) classification. There is broad consensus that these patients are candidates for local ablative treatment strategies with surgery and/or radiot...

Full description

Saved in:
Bibliographic Details
Main Authors: Pouyiourou, Maria (Author) , Wohlfromm, Timothy (Author) , Kraft, Bianca (Author) , Hielscher, Thomas (Author) , Stichel, Damian (Author) , Deimling, Andreas von (Author) , Delorme, Stefan (Author) , Endris, Volker (Author) , Neumann, Olaf (Author) , Stenzinger, Albrecht (Author) , Krämer, Alwin (Author) , Bochtler, Tilmann (Author)
Format: Article (Journal)
Language:English
Published: 11 September 2021
In: European journal of cancer
Year: 2021, Volume: 157, Pages: 179-189
ISSN:1879-0852
DOI:10.1016/j.ejca.2021.08.019
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2021.08.019
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804921005347
Get full text
Author Notes:Maria Pouyiourou, Timothy Wohlfromm, Bianca Kraft, Thomas Hielscher, Damian Stichel, Andreas von Deimling, Stefan Delorme, Volker Endris, Olaf Neumann, Albrecht Stenzinger, Alwin Krämer, Tilmann Bochtler
Description
Summary:Background - Single-site carcinoma of unknown primary (CUP) is recognised as a distinct favourable subtype in the European Society of Medical Oncology (ESMO) classification. There is broad consensus that these patients are candidates for local ablative treatment strategies with surgery and/or radiotherapy, but data on their outcomes are scarce. - Patients and methods - In this study, we have addressed the prospects of cure and prognostic factors in a retrospective cohort of 63 patients who were eligible for local treatment at our centre. - Results - Median event-free (EFS) and overall survival (OS) were 15.6 months and 52.5 months, respectively. Of 61 patients who received local treatment, 20 (32.8%) remained event-free over a median follow-up of 28 months. Baseline clinical parameters including affected organ, number, volume and histology of metastases had no significant impact on prognosis, whereas deleterious TP53 mutations and DNA copy number loss emerged as independent adverse risk factors with respect to EFS. Surgical treatment was associated with improved OS as compared to radiation-based therapy. - Conclusion - Our study advocates to pursue localised treatment with surgery and/or radiotherapy whenever feasible and implies that genetic parameters might additionally determine the clinical course of single-site CUP patients.
Item Description:Gesehen am 11.11.2021
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2021.08.019

Similar Items